We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

BioArctic AB (BIOA B) NPV

Sell:188.60 SEK Buy:189.00 SEK Change: 3.80 SEK (2.06%)
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Sell:188.60 SEK
Buy:189.00 SEK
Change: 3.80 SEK (2.06%)
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Sell:188.60 SEK
Buy:189.00 SEK
Change: 3.80 SEK (2.06%)
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BioArctic AB is a Sweden-based company engaged in the biotechnology sector. The Company focuses on the research and development of treatments, which aim at diseases that affect the central nervous system (CNS). Its therapeutic areas encompass neurodegenerative disorders, Alzheimer's disease, Parkinson's disease, complete spinal cord injury, as well as other CNS disorders. The Company owns a technology platform, which develops a range of therapeutic monoclonal antibodies. The Company's pipeline includes product candidates in various clinical phases, such as BAN2401, AE1501, BAN0805, imaging and biochemical biomarkers, BBB-technology and SC0806. The Company also operates through SpineMedical AB.

Contact details

Address:
Warfvinges vag 35
STOCKHOLM
112 51
Sweden
Telephone:
+46 (8) 6956930
Website:
https://www.bioarctic.se/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
BIOA B
ISIN:
SE0010323311
Market cap:
13.88 billion SEK
Shares in issue:
88.31 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Gunilla Osswald
    Chief Executive Officer
  • Anders Martin-Loef
    Chief Financial Officer
  • Lars Lannfelt
    Director, Senior Vice President University Collaborations
  • Christer Moeller
    Vice President Pre-Clinical Development, Chief Scientific Officer
  • Jan Mattsson
    Vice President - Finance
  • Gunilla Andersson
    Vice President of Human Resources
  • Oskar Bosson
    Vice President, Communications and Investor Relations
  • Mikael Moge
    Vice President - Chemistry, Manufacturing and Control
  • Johanna Falting
    Vice President, Head of Research
  • Anna-kaija Groenblad
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.